Skip to main content
MACROGENICS INC logo

MACROGENICS INC — Investor Relations & Filings

Ticker · MGNX ISIN · US5560991094 LEI · 5493001KJQUA83L8MH79 US Manufacturing
Open in API
Filings indexed 894 across all filing types
Latest filing 2020-02-03 Major Shareholding Noti…
Country US United States of America
Listing US MGNX

About MACROGENICS INC

https://www.macrogenics.com/

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary antibody engineering platforms, including the DART (Dual-Affinity Re-Targeting) and TRIDENT technologies, to create novel product candidates. Its pipeline consists of investigational treatments such as monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific antibodies. MacroGenics maintains fully-integrated capabilities, from research and discovery through to GMP (Good Manufacturing Practice) manufacturing, to advance its portfolio of potential medicines for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-03 English
FORM 4
Director's Dealing
2020-01-31 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions the issuance of a press release about financial expectations and program development priorities, but it does not contain detailed financial statements or comprehensive financial analysis. The document is relatively short (3856 characters) and primarily serves to announce information rather than provide a full financial report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2020-01-09 English
Regulatory Filings 2020
Regulatory Filings
2020-01-06 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a sales agreement for common stock of MacroGenics, Inc. It details an "at the market" offering of up to $50 million in common stock, including terms of the sales agreement, compensation to the sales agent, risk factors, and other offering details. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, management discussion, or any other report type. It is clearly related to financing activities and capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not a brief announcement or regulatory filing. Confidence is high due to explicit references to sales agreement, offering size, and prospectus language.
2020-01-03 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from MacroGenics, Inc. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It references a specific filing (Form S-3) and requests an administrative action (acceleration of effectiveness). The document is short (1259 characters) and is a correspondence related to a regulatory filing, not the filing itself. It does not contain financial data or report content. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and correspondence with the SEC that do not fit other categories.
2019-12-31 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.